Evidence-based prevention (EBP): A review of cytochrome P450 expression in the bronchial epithelium and new approach to lung cancer prevention
- 36 Downloads
The number of fatalities in Japan attributable to lung cancer exceeded 50000 in 2001. It is socially desirable that various markers, which can be utilized for the prevention of lung cancer, be established. We believe that smoking or exposure to carcinogens in air induces mutations in bronchial and alveolar epithelia, leading to the development of lung cancer. It would be useful to have markers of individual differences in susceptibility to chemical carcinogen-induced lung cancer 1) to identify genetic polymorphisms of enzymes metabolizing chemical carcinogens and 2) to investigate the expression of enzymes metabolizing chemical carcinogens. In this paper, we review CYP expression in the bronchial epithelium. CYP1, CYP2 and CYP3 are expressed in the bronchial epithelium. We also show the relationship between the genetic polymorphisms of cytochrome P450 (CYP) and a person’s susceptibility to chemical carcinogen-induced lung cancer. We demonstrate the relationship between cigarette consumption and the CYP expression profile in the bronchial epithelium. To maintain and promote public health, we must apply evidence, such as CYP polymorphisms and CYP profiles to disease prevention and also to aggressively advance evidence-based prevention (EBP) of lung cancer.
Key wordscytochrome P450 (CYP) evidence-based prevention (EBP) lung cancer polymorphism bronchial epithelium
Unable to display preview. Download preview PDF.
- (3).Gu CD, Osaki T, Oyama T, Inoue M, Kodate M, Dobashi K, et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer; Impact on recurrence and survival. Ann Surg. 2001; 233: 133–139.Google Scholar
- (6).Oyma T, Kawamoto T, Matsuno M, Osaki T, Matsumoto A, Isse T, et al. A case-case study comparing the usefulness of serum trace elements (Cu, Zn and Se) and tumor markers (CEA, SCC and SLX) in non-small cell lung cancer patients. Anticancer Res. 2003; 23: 605–612.Google Scholar
- (12).Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, et al. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer. 2005 (in press).Google Scholar
- (16).Kawamoto T, Isse T, Kumugita N, Yang M, Kitagawa K, Suenaga R, et al. Effects of genetic polymorphism of drug metabolizing enzymes on smoking and drinking. J UOEH. 2003; 25: 97–106.Google Scholar
- (22).Oyama T, Kawamoto T, Mizoue T, Nishida K, Osaki T, Sugio K, et al. p53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms. Int J. Oncol. 1997; 11: 305–309.Google Scholar